NUK - logo
E-viri
Recenzirano Odprti dostop
  • CCR2 deficiency alters acti...
    Somebang, Kerri; Rudolph, Joshua; Imhof, Isabella; Li, Luyi; Niemi, Erene C.; Shigenaga, Judy; Tran, Huy; Gill, T. Michael; Lo, Iris; Zabel, Brian A.; Schmajuk, Gabriela; Wipke, Brian T.; Gyoneva, Stefka; Jandreski, Luke; Craft, Michael; Benedetto, Gina; Plowey, Edward D.; Charo, Israel; Campbell, James; Ye, Chun Jimmie; Panter, S. Scott; Nakamura, Mary C.; Eckalbar, Walter; Hsieh, Christine L.

    Cell reports (Cambridge), 09/2021, Letnik: 36, Številka: 12
    Journal Article

    In traumatic brain injury (TBI), a diversity of brain resident and peripherally derived myeloid cells have the potential to worsen damage and/or to assist in healing. We define the heterogeneity of microglia and macrophage phenotypes during TBI in wild-type (WT) mice and Ccr2−/− mice, which lack macrophage influx following TBI and are resistant to brain damage. We use unbiased single-cell RNA sequencing methods to uncover 25 microglia, monocyte/macrophage, and dendritic cell subsets in acute TBI and normal brains. We find alterations in transcriptional profiles of microglia subsets in Ccr2−/− TBI mice compared to WT TBI mice indicating that infiltrating monocytes/macrophages influence microglia activation to promote a type I IFN response. Preclinical pharmacological blockade of hCCR2 after injury reduces expression of IFN-responsive gene, Irf7, and improves outcomes. These data extend our understanding of myeloid cell diversity and crosstalk in brain trauma and identify therapeutic targets in myeloid subsets. Display omitted •TBI elevates distinct phenotypes of microglia, macrophages, and dendritic cells•Ccr2 deficiency alters cell proportions and reduces ISG expression in microglia•TBI induces crosstalk between microglia and circulating monocytes•Preclinical translational studies to target human CCR2 after TBI improves outcomes By single-cell RNA sequencing of traumatically injured and normal brains from wild-type and Ccr2−/− mice, Somebang et al. define microglia, macrophage, and dendritic cell phenotypes in TBI. Targeting mouse and/or human CCR2 reduces specific TBI brain CNS myeloid compartments, dampens type I interferon responses, and improves cognition after TBI.